NIH lutein study
This article was originally published in The Tan Sheet
Executive Summary
The second Age-Related Eye Disease Study (AREDS II) is slated to begin in Spring 2006, according to its sponsor, the National Eye Institute. The Phase III clinical trial will investigate whether oral supplementation with lutein (10 mg/day) and zeaxanthin (2 mg/day) and/or lutein and zeaxanthin in combination with omega-3 fatty acids (1 g/day) will slow the progression of age-related macular degeneration (AMD) when compared to placebo. Participants will be at moderate to high risk of AMD. The supplements' effect on cataract surgery also will be examined. To date, more than $4 mil. in funding has been awarded. The study builds off the first AREDS, which found that high-dose combination of antioxidants and zinc can lower the risk of developing advanced AMD in high-risk patients (1"The Tan Sheet" Oct. 15, 2001, p. 3)...
You may also be interested in...
AREDS II update
The National Eye Institute has enrolled 2,907 people aged 50 to 85 years with high risk of advanced macular degeneration to participate in the Age Related Eye Disease Study II, and researchers expect to complete enrollment by April, according to Dr. Traci Clemons at the SupplySide West trade show in Las Vegas Nov. 6. Clemons, senior statistician for the EMMES Corporation, the firm overseeing the study, updated seminar attendees on the the study's progress, which aims to evaluate the efficacy of lutein and zeanxanthin and/or lutein and zeanxanthin in combination with omega-3 fatty acids on progression to AMD (1"The Tan Sheet" Jan. 9, 2006, In Brief). Researchers will enroll approximately 4,000 subjects and conclude the study in 2013, five years after the last patient is enrolled...
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study
Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.